{"id":"low-dose-valproate","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea and gastrointestinal upset"},{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Thrombocytopenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Valproic acid is a short-chain fatty acid that acts as a histone deacetylase inhibitor at therapeutic doses. At lower doses, it may preferentially modulate specific signaling pathways and gene expression patterns relevant to various disease states. The mechanism at low doses is thought to involve epigenetic modifications that can reduce inflammation, enhance differentiation, or inhibit proliferation depending on the target tissue.","oneSentence":"Low-dose valproate inhibits histone deacetylases (HDACs) and enhances histone acetylation, leading to altered gene expression and potential anti-inflammatory or anti-proliferative effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:53:32.202Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cancer (various types, under investigation)"},{"name":"Neurological and inflammatory conditions (under investigation)"}]},"trialDetails":[{"nctId":"NCT04274179","phase":"PHASE3","title":"Ketogenic Diet for New-Onset Absence Epilepsy","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2020-08-10","conditions":"Absence Epilepsy, Ketogenic Dieting, Epilepsy, Absence","enrollment":40},{"nctId":"NCT03689114","phase":"PHASE4","title":"Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy(STANDLOW)","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2021-05-10","conditions":"Epilepsies, Partial","enrollment":58},{"nctId":"NCT05263674","phase":"PHASE3","title":"Fast Acute Sedation at Intensive Care vs. High-dose i.v. Anti-seizure Medication for Treatment of Non-convulsive Status Epilepticus (FAST-trial)","status":"RECRUITING","sponsor":"University of Southern Denmark","startDate":"2022-02-07","conditions":"Non-Convulsive Status Epilepticus","enrollment":140},{"nctId":"NCT06020898","phase":"PHASE2","title":"Sodium Valproate in Patients With Acute Ischemic Stroke","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2023-09-01","conditions":"Acute Ischemic Stroke","enrollment":40},{"nctId":"NCT04729543","phase":"PHASE1, PHASE2","title":"MAGE-C2 TCR T Cell Trial to Treat Melanoma and Head and Neck Cancer","status":"RECRUITING","sponsor":"Erasmus Medical Center","startDate":"2020-10-20","conditions":"Melanoma, Melanoma, Uveal, Head and Neck Cancer","enrollment":20},{"nctId":"NCT03616223","phase":"PHASE1, PHASE2","title":"FX-322 in Sensorineural Hearing Loss","status":"COMPLETED","sponsor":"Frequency Therapeutics","startDate":"2018-07-03","conditions":"Sensorineural Hearing Loss","enrollment":23},{"nctId":"NCT02056236","phase":"NA","title":"TELSTAR: Treatment of ELectroencephalographic STatus Epilepticus After Cardiopulmonary Resuscitation","status":"COMPLETED","sponsor":"University of Twente","startDate":"2014-04","conditions":"Cardiac Arrest, Anoxic Encephalopathy, Status Epilepticus","enrollment":172},{"nctId":"NCT04035798","phase":"PHASE2, PHASE3","title":"add-on Low Dose Memantine in Middle-to-old Aged Bipolar II Disorder Patients","status":"UNKNOWN","sponsor":"National Cheng-Kung University Hospital","startDate":"2019-08-01","conditions":"Bipolar II Disorder","enrollment":120},{"nctId":"NCT00414310","phase":"PHASE2","title":"Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-12","conditions":"Myelodysplastic Syndrome, Acute Myelogenous Leukemia","enrollment":153},{"nctId":"NCT00867672","phase":"PHASE2","title":"Study of Decitabine Alone or in Combination With Valproic Acid and All-trans Retinoic Acid in Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"University Hospital Freiburg","startDate":"2011-08","conditions":"Acute Myeloid Leukemia","enrollment":204},{"nctId":"NCT00807989","phase":"PHASE4","title":"The Efficacy and Safety of Low Dose Combination of LTG and VPA Compared to CBZ Monotherapy","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2008-03","conditions":"Epilepsy","enrollment":207},{"nctId":"NCT00995332","phase":"PHASE1, PHASE2","title":"Disease Stabilization in AML by Treatment With ATRA, Valproic Acid and Low-dose Cytarabine","status":"COMPLETED","sponsor":"University of Bergen","startDate":"2009-09","conditions":"Acute Myelogenous Leukemia","enrollment":36},{"nctId":"NCT00107458","phase":"PHASE1","title":"Valproic Acid in Treating Young Patients With Recurrent or Refractory Solid Tumors or CNS Tumors","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2005-05","conditions":"Brain and Central Nervous System Tumors, Unspecified Childhood Solid Tumor, Protocol Specific","enrollment":26},{"nctId":"NCT00382590","phase":"PHASE2","title":"Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) Patients","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2005-08","conditions":"Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Leukemia","enrollment":11},{"nctId":"NCT00496444","phase":"PHASE1","title":"Azacytidine and Valproic Acid in Patients With Advanced Cancers","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2005-05","conditions":"Advanced Cancers","enrollment":69},{"nctId":"NCT01295593","phase":"PHASE1, PHASE2","title":"Low Dose CdA Combined With Valproic Acid (VPA) in Previously Treated B-cell Chronic Lymphocytic Leukemia(B-CLL)","status":"UNKNOWN","sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","startDate":"2010-12","conditions":"Chronic Lymphocytic Leukemia","enrollment":33}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Low valproate"],"phase":"marketed","status":"active","brandName":"Low dose valproate","genericName":"Low dose valproate","companyName":"Mario Negri Institute for Pharmacological Research","companyId":"mario-negri-institute-for-pharmacological-research","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Low-dose valproate inhibits histone deacetylases (HDACs) and enhances histone acetylation, leading to altered gene expression and potential anti-inflammatory or anti-proliferative effects. Used for Cancer (various types, under investigation), Neurological and psychiatric disorders (off-label/investigational).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}